Integrating Novel Targeted Agents Into Platinum-Resistant Ovarian Cancer Clinical Practice CME/CNE/CPE Saturday, 24 October 2026, 18:30 - 20:00 CEST PAMPLONA AUDITORIUM, HALL 5, IFEMA MADRID, MADRID, SPAIN

https://events.medscapelive.org/website/98737/?utm_campaign=464425.01a_esmo_email&utm_source=edu&utm_medium=em&utm_content=ext Join us in Madrid as our expert faculty address the critical need for advanced therapeutic strategies in platinum-resistant ovarian cancer (PROC). This session will provide clinicians with a comprehensive review of the latest clinical trial evidence surrounding novel antibody–drug conjugates and the safety profiles of emerging immunotherapy–chemotherapy combinations. Participants will enhance their clinical competence in translating biomarker testing results into personalized therapeutic choices. Don’t miss the opportunity to bridge the gap between groundbreaking clinical data and real-world, patient-centered PROC management.